Sort
82,697 grants matching “vaccine development”
EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY
$5,415,727Marianne Ward · Duke University · N01 · FY2015 · AI
HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVD
$5,415,284Charles Nicolette · Argos Therapeutics, Inc. · N01 · FY2013 · AI
Task 2/D23: Nonhuman Primate Model Development for Poliovirus
$5,414,197 · N01 · FY2009 · AI
Duke Center for HIV Structural Biology
$5,412,818Priyamvada Acharya · Duke University · U54 · FY2024 · AI
Consortium for Immunotherapeutics Against Viral Hemorrhagic Fevers
$5,407,592Erica Ollmann Saphire · Scripps Research Institute, The · U19 · FY2018 · AI
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit
$5,406,746Magdalena Elzbieta Sobieszczyk · Columbia University Health Sciences · UM1 · FY2020 · AI
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP
$5,400,000Fred Hutchinson Cancer Research Center · U01 · FY2005 · AI
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$5,397,843Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Project 3 â Direct-Acting Antivirals against Paramyxoviruses
$5,393,007Benhur Lee · Emory University · U19 · FY2022 · AI
Convalescent Plasma to Limit Coronavirus Associated Complications: Randomized Blinded Phase 2 Study Comparing Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 Hospitalized Patients
$5,391,810Ralph Lewis Sacco · University Of Miami School Of Medicine · UL1 · FY2020 · TR
Vitrification-stabilized Multivalent Botulinum Vaccines
$5,388,306Dynport Vaccine Company, Llc · UC1 · FY2004 · AI
HIV Prevention Trials Network: Network Laboratory
$5,382,404Susan H Eshleman · Johns Hopkins University · UM1 · FY2011 · AI
HIV VACCINE TRIALS NETWORK LEADERSHIP GROUP
$5,370,001Fred Hutchinson Cancer Research Center · U01 · FY2003 · AI
Pandemic Influenza Translational Research and novel universal countermeasure development
$5,343,633Matthew Memoli · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY
$5,335,971Marianne Ward · Duke University · N01 · FY2014 · AI
B-cell Biology of Mucosal Immune Protection from SIV Challenge
$5,335,074Eric Hunter · Emory University · U19 · FY2014 · AI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
$5,334,612Douglas F Nixon · George Washington University · UM1 · FY2017 · AI
DCTD Biopharmaceutical Development
$5,333,006David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA
Immunoprophylactic Strategies to Control Emerging Enteric Infections
$5,313,722Myron Max Levine · University Of Maryland Baltimore · U19 · FY2016 · AI
UZ-UCSF CTU
$5,312,671Zvavahera Mike Chirenje · University Of California, San Francisco · UM1 · FY2022 · AI
Immunoprophylactic Strategies to Control Emerging Enteric Infections
$5,312,643Myron Max Levine · University Of Maryland Baltimore · U19 · FY2017 · AI
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
$5,308,961Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2025 · AG
Harnessing CD4+ T cell responses for long-term protective immunity against HIV
$5,307,361Rafi Ahmed · Scripps Research Institute, The · UM1 · FY2012 · AI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)
$5,303,243Joseph J. Eron · Univ Of North Carolina Chapel Hill · U01 · FY2010 · AI
Manufacture a protein encoding CAP256.wk34.c80 OPT4 envelope for induction of V2 Apex bnAbs
$5,303,216Barton F Haynes · Duke University · UM1 · FY2024 · AI